About standardization of L-lysinum 3-methyl-1,2,4-thiazolyl-5-thioacetate tablets


  • O. S. Bidnenko Zaporizhzhia State Medical University,
  • L. I. Kucherenko Zaporizhzhia State Medical University,
  • I. A. Mazur Zaporizhzhia State Medical University,
  • G. I. Tkachenko Zaporizhzhia State Medical University,




L-lysine-3-methyl-1, 2, 4-triazolyl-5-thioacetat, Quantitative Determination, Tablets, Spectrophotometry


Ischemic heart disease is the leader of a sad medical statistics. According to official data, it is the most common disease on the planet. The majority of adults tend to it. Metabolic disorders are at the heart of pathological processes that develop in the myocardium during ischemia. Medicines that are able to interrupt or reduce the ischemic unfavorable metabolic reactions cascade, which are united as "metabolite tropic cardio protectors" exert a protective effect on the myocardium and have undoubted promise in clinical practice. The members of SPA "Farmatron" conducted targeted search of cardio protection drugs in a series of derivatives of 1,2,4-thiazolyl-5-thio carboxylic acids, which was finished by creation of L-lysiny 3-methyl-1,2,4-thiazolyl-5-thioacetate that shows cardio protective, antiischemic, antioxidant and pronounced effect on the vascular endothelium of brain and heart. Therefore, rational drug dosage form – tablet – is chosen for new drug. L-lysiny 3-methyl-1,2,4-thiazolyl-5-thioacetate is one of the metabolite tropic drugs that has properties of both direct and indirect cardio protectors. It is well known that medications for the treatment of cardiovascular disease in most cases should be used during a long time, and even lifelong. Therefore, rational drug dosage form – tablet – is chosen for new drug.

The aim of our study was to develop methods for standardization, including identification and quantitative determination of the active ingredient in the tablets obtained by spectrophotometric method.

Materials and methods. We investigated a tablet containing 200 mg of active ingredient obtained in the laboratory setting, and conducted six experiments. The study found that the active ingredient content is in the range of 0.2002 to 0.2016, spectrophotometric study results are consistent with the requirements of the State Pharmacopoeia of Ukraine.

Conclusions. Under the studies we developed a sensitive, objective, reliable, reproducible method for spectrophotometric determination of L-lysiny 3-methyl-1,2,4-thiazolyl-5-thioacetate.


Bidnenko, O. S., Kucherenko, L. I., Mazur, I. A., & Tkachenko, H. I. (2016) Shchodo standartyzatsii tabletkovoi masy L-lizynii 3-metyl-1,2,4-tryazolil-5-tioatsetat [About standardization of L-lysinum 3-methyl-1,2,4-thiazolyl-5-thioacetate tablet mass]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky; 1, 35–39. [in Ukrainian].

Georgievskij, G. V. (2011) Razrabotka kompleksa fiziko-khimicheskikh metodik, obespechivayuschikh sozdanie i kontrol' kachestva original'nykh otechestvennykh preparatov, proizvodnykh 1,2,4-triazola [Development of the complex physical and chemical methods, ensuring the creation and control of the quality of the original domestic products, 1,2,4-triazole]. Zaporozhskij medicinskij zhurnal, 13(1), 58–69. [in Ukrainian].

Derzhavne pidpryiemstvo «Naukovo-ekspertnyi farmakopeinyi tsentr» (2008) Derzhavna Farmakopeia Ukrainy [State Ukrainian Pharmacopeia]. Kharkiv, 2. [in Ukrainian].

Kovalenko, V. N. (Ed.) (2012) Kompendium. Lekarstvennye preparaty 2012 [Compendium. Medicinal Preparations. 2012]. Kyiv: Morion. [in Ukrainian].

Kucherenko, L. I., Khromylova, O. V., Moryak, Z. B., Tkachenko, G. I., & Vaschenko, O. V. (2014) Shchodo postadiinoho kontroliu vyrobnytstva tabletok [Stage control of tablets manufacturing]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky, 2, 31–34. [in Ukrainian].

Mazur, I. A., Chekman, I. S., Belenichev, I. F., & Voloshin, N. A. (2007) Metabolitotropnye preparaty [Metabolitotropnye drugs]. Zaporizhzhya. [in Ukrainian].

Mazur, I. A., Belenichev, I. F., Kucherenko, L. I., Bukhtiyarova, N. V., Georgievskij, G. V., Pavlyuk, I. V., & Steblyuk, V. S. (2012) Podkhody k razrabotke i sozdaniyu metabolitotropnykh preparatov – proizvodnykh 1,2,4-triazola [Approaches to the development and creation of metabolitotropnyh drugs - derivatives of 1,2,4-triazole]. Farmakom, 3, 78–82. [in Ukrainian].

(2007) European Pharmacopoeia. Strasbourg.

Sevgi, T. U., & Fikriye, T. E. (2010) Spectrophotometric method for the determination, validation, spectroscopic and thermal analysis of diphenhydramine in pharmaceutical preparation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 77, 324–329.

White, W. (2011) Blood pressure monitoring in cardiovascular medicine and therapeutscs. New Jersey: Humana Press.

How to Cite

Bidnenko OS, Kucherenko LI, Mazur IA, Tkachenko GI. About standardization of L-lysinum 3-methyl-1,2,4-thiazolyl-5-thioacetate tablets. CIPM [Internet]. 2016Jun.10 [cited 2023Dec.10];(2). Available from: http://pharmed.zsmu.edu.ua/article/view/70708



Analysis and standardization of biologycally active substances and dosage forms